Literature DB >> 29030167

Turnaround time of whole genome sequencing for mycobacterial identification and drug susceptibility testing in routine practice.

I D Olaru1, H Patel2, K Kranzer3, N Perera2.   

Abstract

OBJECTIVES: Until recently whole genome sequencing (WGS) for mycobacteria has been restricted mostly to the research setting. However, in 2017 Public Health England has implemented WGS for routine mycobacterial identification and susceptibility testing for Mycobacterium tuberculosis. Our objective was to evaluate the impact of this change on the laboratory turnaround times and availability of results.
METHODS: Over the years 2016 and 2017, the period 1 January to 30 April was selected to represent before and after implementation of WGS. Prior to 2017, line probe assays were used for mycobacterial species identification. Turnaround times for the different steps of the diagnostic process were evaluated for all positive mycobacterial cultures that were sent from our hospital to the Reference Laboratory during the study period.
RESULTS: A total of 161 positive mycobacterial cultures were sent to the Reference Laboratory. Half of the isolates (n=81/161, 50%) were M. tuberculosis and 80/161 (50%) were non-tuberculous mycobacteria. The median number of workdays for mycobacterial species identification was 1 day (interquartile range (IQR) 1-3) in 2016 and 6 days (IQR 5-7) in 2017, p <0.001. For M. tuberculosis complex, the median time to drug susceptibility testing results, either molecular or phenotypic, was 12 days (IQR 11-18) in 2016 and 8 days (IQR 7-10) in 2017, p <0.001.
CONCLUSIONS: Routine WGS performed well in this setting for mycobacterial identification and susceptibility testing for M. tuberculosis and decreased time to drug susceptibility testing results. There was an increase in turnaround times for species identification using WGS, when compared with the previous methods.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mycobacteria; TB; Tuberculosis; WGS; Whole genome sequencing

Mesh:

Year:  2017        PMID: 29030167     DOI: 10.1016/j.cmi.2017.10.001

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Simple Identification of Mycobacterial Species by Sequence-Specific Multiple Polymerase Chain Reactions.

Authors:  Nihan Unubol; Inci Tuney Kizilkaya; Sinem Oktem Okullu; Kaya Koksalan; Tanil Kocagoz
Journal:  Curr Microbiol       Date:  2019-05-09       Impact factor: 2.188

2.  Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics?

Authors:  Sagal Mohamed; Claudio U Köser; Max Salfinger; Wladimir Sougakoff; Scott K Heysell
Journal:  Eur Respir J       Date:  2021-03-18       Impact factor: 16.671

3.  Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance.

Authors:  Mirae Park; Ajit Lalvani; Giovanni Satta; Onn Min Kon
Journal:  BMC Infect Dis       Date:  2022-04-07       Impact factor: 3.090

4.  Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study.

Authors:  Iris Finci; Audrey Albertini; Matthias Merker; Sönke Andres; Nino Bablishvili; Ivan Barilar; Tatiana Cáceres; Valeriu Crudu; Eduardo Gotuzzo; Nchimunya Hapeela; Harald Hoffmann; Christine Hoogland; Thomas A Kohl; Katharina Kranzer; Anna Mantsoki; Florian P Maurer; Mark P Nicol; Ecaterina Noroc; Sara Plesnik; Timothy Rodwell; Morten Ruhwald; Theresa Savidge; Max Salfinger; Elizabeth Streicher; Nestani Tukvadze; Robin Warren; Widaad Zemanay; Anna Zurek; Stefan Niemann; Claudia M Denkinger
Journal:  Lancet Microbe       Date:  2022-07-27

5.  Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial.

Authors:  Annelies Van Rie; Elise De Vos; Emilyn Costa; Lennert Verboven; Felex Ndebele; Tim H Heupink; Steven Abrams; Boitumelo Fanampe; Anneke Van der Spoel Van Dyk; Salome Charalambous; Gavin Churchyard; Rob Warren
Journal:  Trials       Date:  2022-10-08       Impact factor: 2.728

6.  Identification of pathogen(s) in infectious diseases using shotgun metagenomic sequencing and conventional culture: a comparative study.

Authors:  Huan Chen; Jun Li; Shanshan Yan; Hui Sun; Chuyi Tan; Meidong Liu; Ke Liu; Huali Zhang; Mingxiang Zou; Xianzhong Xiao
Journal:  PeerJ       Date:  2021-06-29       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.